By Tom Whitfield

A Cureus perspective has organized Indian atopic dermatitis care into a four-step sequence. The open-access journal published "Holistic Skincare Approach of Cleanse–Treat–Moisturize–Protect (CTMP®) in Atopic Dermatitis Management: Indian Perspectives, Evidence, and Future Directions."

CTMP® stands for Cleanse, Treat, Moisturize, Protect. The title frames the paper as a holistic protocol tailored to Indian clinical realities. It signals a dual purpose: synthesis of existing evidence plus a roadmap for future Indian cohort research.

What does the framework cover?

The acronym sequences daily skincare into four actions that map onto atopic dermatitis pathophysiology. Cleanse addresses surfactant choice, water hardness and pH. Treat covers prescription topicals including corticosteroids, calcineurin inhibitors, and newer non-steroidal options. Moisturize focuses on emollient selection, occlusive layering, and application frequency. Protect targets environmental triggers such as UV, particulate pollution, sweat, and indoor allergens.

The "holistic" framing means the authors treat the four steps as a single integrated intervention rather than independent choices. That's because atopic dermatitis patients often self-substitute across categories when given separate instructions. CTMP® locks the sequence into a recallable routine that travels between home, school, and clinic.

Why does the paper single out India?

The title's "Indian Perspectives" clause signals a country-specific scope. Indian atopic dermatitis care operates against a backdrop of urban-rural split, dense specialist access in metros, and thin coverage in many districts. Imported European or U.S. guidelines, written for temperate climates, often need translation.

Hot-humid conditions, hard water in many regions, and year-round particulate pollution complicate emollient tolerability and trigger profiles. The CTMP® framework, as titled, positions itself as adaptable across these settings. That's because each step can be filled with widely available pharmacy products rather than prescription-only imports.

What does the "Evidence" section contain?

The paper is a perspective, not a primary trial, and the title gives no hint of new PASI, EASI or SCORAD endpoints. Instead, it synthesizes published work on cleanser pH, moisturizer formulations, and barrier repair, mapping those findings onto the four-step sequence. The value lies in curation, not in fresh data.

That distinction matters for readers scanning the abstract. Practicing dermatologists looking for effect sizes will need to follow the paper's reference list into the primary literature, because the perspective itself supplies synthesis, not deltas.

What research does the paper call for?

The "Future Directions" tail names a research agenda. The authors ask for prospective Indian cohort studies that score CTMP® adherence against EASI, SCORAD or POEM. They also call for head-to-head trials of locally manufactured cleansers and moisturizers against international brands. They flag a need for pediatric-specific data, since most atopic dermatitis presents in childhood.

How should a clinician use CTMP® today?

The framework functions as a teaching mnemonic. The acronym gives patients a four-step routine they can recite, and it gives clinicians a four-question follow-up checklist: what cleanses, what treats, what moisturizes, and what protects. The paper is open access through Cureus, so any Indian practitioner with internet access can pull it.

For U.S. or European readers, CTMP® reads as a packaging of what most guidelines already say. Its novelty lies in country-specific sequencing, not in mechanism.

What's the takeaway?

CTMP® won't replace prescription therapy for moderate-to-severe atopic dermatitis, but it gives Indian dermatologists a low-cost teaching tool that fits the country's pharmacy shelves. The real test will be whether the authors' call for prospective validation draws funding and produces the EASI deltas they're asking for.